Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of subcutaneous vedolizumab maintenance in moderate to severe Crohn's disease after response to open-label intravenous induction
MOH_2017-01-05_000039Phase 3Recruiting
- Sponsor
- Takeda
- Start
- Sep 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Crohn's disease comparing Vedolizumab SC maintenance with Placebo SC maintenance (2 arms). Primary endpoint: Clinical remission at week 52. Started Sep 2016; status: recruiting.
02
Drugs
vedolizumab
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on MOH_2017-01-05_000039.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2017-01-05_000039.